Side-by-Side Comparison
Sermorelin vs Tesamorelin: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Sermorelin and Tesamorelin differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: Geref, GHRH(1-29)NH2
A growth hormone-releasing hormone analog with a long history of clinical use for GH deficiency diagnosis and therapy.
Also: Egrifta, TH9507
An FDA-approved GHRH analog used for HIV-associated lipodystrophy, with research into broader metabolic and cognitive applications.
Side-by-side comparison
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Primary mechanism | GHRH Receptor Agonism | GHRH Receptor Agonism |
| FDA status | FDA Approved | FDA Approved |
| Evidence level | Strong Clinical Evidence | FDA Approved |
| Human trials | Yes (15+ indexed) | Yes (12+ indexed) |
| Studies indexed | 51 total (22 human, 15 animal) | 36 total (18 human, 8 animal) |
| Primary uses researched | Growth hormone stimulation, Anti-aging, Sleep quality, Body composition | Visceral fat reduction, HIV lipodystrophy, Cognitive function (research) |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 3357.93 Da | 5135.93 Da |
| Amino acids | 29 | 44 |
| Category | growth hormone | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. Both compounds share the same primary mechanism (ghrh receptor agonism), so differences between them are driven by pharmacokinetics, selectivity, and clinical data rather than mechanism class.
Regulatory status. Both compounds share the same FDA status (FDA Approved), which means the practical pathway to access is similar for each.
Evidence base. Tesamorelin sits at a higher evidence level (L5) than Sermorelin (L4) under PeptideMark's L1–L5 methodology.
Research focus. Published research on Sermorelin has concentrated on growth hormone stimulation, anti-aging, sleep quality. Research on Tesamorelin has concentrated on visceral fat reduction, hiv lipodystrophy, cognitive function (research). These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Documented effects | 6 total | 9 total |
| Serious events | 0 | 0 |
| Common events | 1 | 5 |
| Black box warning | No | No |
| Contraindications | 3 listed | 4 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
Sermorelin
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L4)
- Multiple human clinical trials (15+ indexed)
Limitations
- Prohibited in competitive sport under WADA
Tesamorelin
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (12+ indexed)
Limitations
- Prohibited in competitive sport under WADA
Representative studies
Sermorelin
Two years of continuous subcutaneous infusion of GHRH(1-29)NH2 in GH deficient adults
Vittone J, et al. · Pituitary (1997)
Two years of sermorelin treatment maintained increased IGF-1 levels and improved lean body mass in GH-deficient adults.
PubMed 9452117Sermorelin Acetate Treatment in Growth Hormone Deficient Children: 2-Year Randomized Double-Blind Trial
Laron Z, Parks JS, Adler GK, et al. · Journal of Clinical Endocrinology & Metabolism (1995)
Sermorelin increased mean height velocity from 4.2 to 8.1 cm/year and serum IGF-1 by 247% compared to baseline; sustained over 24 months.
PubMed 7852385Tesamorelin
Tesamorelin, a Growth Hormone–Releasing Factor Analogue, Reduces Visceral Fat in HIV-Infected Patients
Falutz J, et al. · Annals of Internal Medicine (2007)
Tesamorelin reduced visceral adipose tissue by 15.4% compared to placebo, without worsening glucose tolerance.
PubMed 17909207REDUCE-1: Tesamorelin in HIV-Associated Lipodystrophy — A Randomized Controlled Trial
Grunfeld C, Thompson M, Brown SJ, et al. · AIDS (2006)
Tesamorelin reduced visceral AT by 18.3% versus 8.3% placebo (p<0.001); improvement sustained at 26 weeks post-treatment.
PubMed 16816556Frequently asked
What is the main difference between Sermorelin and Tesamorelin?
Sermorelin is a growth hormone-releasing hormone analog with a long history of clinical use for gh deficiency diagnosis and therapy. Its primary mechanism is ghrh receptor agonism. Tesamorelin is an fda-approved ghrh analog used for hiv-associated lipodystrophy, with research into broader metabolic and cognitive applications. Its primary mechanism is ghrh receptor agonism. The two differ in regulatory status (FDA Approved vs FDA Approved), strength of evidence (L4 vs L5), and the primary conditions for which each is researched.
Is Sermorelin or Tesamorelin FDA approved?
Sermorelin: Previously FDA-approved as a diagnostic agent for GH deficiency (Geref). The commercial product was discontinued but sermorelin remains available through compounding pharmacies. Tesamorelin: FDA-approved in 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
How does the evidence base compare?
Sermorelin has 51 indexed studies (22 human, 15 animal) and is rated Strong Clinical Evidence. Tesamorelin has 36 indexed studies (18 human, 8 animal) and is rated FDA Approved. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Sermorelin and Tesamorelin be compared directly?
Yes — both compounds share the growth hormone category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are Sermorelin and Tesamorelin commonly stacked together?
There is no widely documented stacking protocol combining Sermorelin and Tesamorelin in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Sermorelin or Tesamorelin?
Sermorelin has 6 documented side effects (0 serious). Tesamorelin has 9 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Sermorelin and Tesamorelin administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, Sermorelin or Tesamorelin?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Sermorelin is most researched for growth hormone stimulation and anti-aging; Tesamorelin is most researched for visceral fat reduction and hiv lipodystrophy. FDA status also matters: FDA Approved for Sermorelin vs FDA Approved for Tesamorelin. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Sermorelin →
Full profile
Tesamorelin →